Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis
- 92 Downloads
Alterations in complex lipids may be involved in pathophysiology of schizophrenia spectrum disorders. Previously, we demonstrated importance of detecting lipid metabolism dysregulation by acylcarnitine (ACs) profile analysis in patients with first-episode psychosis (FEP). The aim of this study was to adopt lipidomics to identify serum glycerophospholipids (GPLs) and sphingomyelins (SMs) for describing FEP status before and after 7-month antipsychotic treatment. Using mass spectrometry and liquid chromatography technique, we profiled 105 individual lipids [14 lysophosphatidylcholines (LysoPCs), 76 phosphatidylcholines (PCs) and 15 SMs] in serum samples from 53 antipsychotic-naïve FEP patients, 44 of them were studied longitudinally and from 37 control subjects (CSs). Among the identified and quantified metabolites one LysoPC was elevated, and contrary the levels of 16 PCs as well as the level of one SM were significantly (p ≤ 0.0005) reduced in antipsychotic-naïve FEP patients compared to CSs. Comparison of serum lipids profiles of FEP patients before and after 7-month antipsychotic treatment revealed that 11 GPLs (2 LysoPCs, 9 PCs), and 2 SMs were found to be significantly changed (p ≤ 0.0005) in which GPLs were up-regulated, and SMs were down-regulated. However, no significant differences were noted when treated patient’s serum lipid profiles were compared with CSs. Our findings suggest that complex lipid profile abnormalities are specifically associated with FEP and these discrepancies reflect two different disease-related pathways. Our findings provide insight into lipidomic information that may be used for monitoring FEP status and impact of the treatment in the early stage of the schizophrenia spectrum disorder.
KeywordsFirst-episode psychosis Lipidomics Glycerophospholipids Lysophosphatidylcholines Phosphatidylcholines Sphingomyelins
This research was supported by the European Union through the European Regional Development Fund (Project no. 2014-2020.4.01.15-0012), and grants from the Estonian Research Foundation (IUT 20-41, IUT 20-42). The funding sources do not have any role in the writing of the manuscript or the decision to submit it for the publication.
LH, EV and MZ designed the study. LH, LL, MP and SJ contributed to data collection and carried out the literature search. MZ and KK were responsible for metabolomics measurements. LH, EV and MZ co-wrote the first draft of the report. LL, MP, SJ, KK, LH, EV, MZ critically revised the manuscript. EV and MZ obtained the research funding. All authors reviewed the manuscript for important intellectual content and approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
The protocol of this study was approved by the Ethics Review Committee on Human Research of the University of Tartu (Estonia). All subjects gave written informed consent in accordance with the Declaration of Helsinki.
- 8.Han X (2016) Lipidomics: comprehensive mass spectrometry of lipids. Wiley, HobokenGoogle Scholar
- 9.Kriisa K, Leppik L, Balõtšev R, Ottas A, Soomets U, Koido K, Volke V, Innos J, Haring L, Vasar E, Zilmer M (2017) Profiling of acylcarnitines in first episode psychosis before and after antipsychotic treatment. J Proteome Res 16:3558–3566. https://doi.org/10.1021/acs.jproteome.7b00279 CrossRefPubMedGoogle Scholar
- 10.Stegemann C, Pechlaner R, Willeit P, Langley SR, Mangino M, Mayr U, Menni C, Moayyeri A, Santer P, Rungger G, Spector TD, Willeit J, Kiechl S, Mayr M (2014) Lipidomics profiling and risk of cardiovascular disease in the prospective population-based bruneck study. Circulation 129:1821–1831. https://doi.org/10.1161/CIRCULATIONAHA.113.002500 CrossRefPubMedGoogle Scholar
- 11.Paapstel K, Kals J, Eha J, Tootsi K, Ottas A, Piir A, Jakobson M, Lieberg J, Zilmer M (2018) Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis. Nutr Metab Cardiovasc Dis 28:44–52. https://doi.org/10.1016/j.numecd.2017.07.011 CrossRefPubMedGoogle Scholar
- 14.Lipid Library website (2009) https://web.archive.org/web/20090531115217/http://www.lipidlibrary.co.uk/Lipids/pc/index.htm. Accessed 27 Apr 2018
- 17.Schwarz E, Prabakaran S, Whitfield P, Major H, Leweke FM, Koethe D, McKenna P, Bahn S (2008) High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res 7:4266–4277. https://doi.org/10.1021/pr800188y CrossRefPubMedGoogle Scholar
- 19.Weber-Fahr W, Englisch S, Esser A, Tunc-Skarka N, Meyer-Lindenberg A, Ende G, Zink M (2013) Altered phospholipid metabolism in schizophrenia: a phosphorus 31 nuclear magnetic resonance spectroscopy study. Psychiatry Res Neuroimaging 214:365–373. https://doi.org/10.1016/j.pscychresns.2013.06.011 CrossRefGoogle Scholar
- 21.Aquino A, Alexandrino GL, Guest PC, Augusto F, Gomes AF, Murgu M, Steiner J, Martins-de-Souza D (2018) Blood-based lipidomics approach to evaluate biomarkers associated with response to olanzapine, risperidone, and quetiapine treatment in schizophrenia patients. Front Psychiatry. https://doi.org/10.3389/fpsyt.2018.00209 CrossRefPubMedPubMedCentralGoogle Scholar
- 22.Orešič M, Tang J, Seppänen-Laakso T, Mattila I, Saarni SE, Saarni SI, Lönnqvist J, Sysi-Aho M, Hyötyläinen T, Perälä J, Suvisaari J (2011) Metabolome in schizophrenia and other psychotic disorders: a general population-based study. Genome Med 3:19. https://doi.org/10.1186/gm233 CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Fukuzako H, Kodama S (1999) Changes in levels of phosphorus metabolites in temporal lobes of drug-naive schizophrenic patients. Am J Psychiatry 4:1205–1208Google Scholar
- 25.Matsumoto J, Sugiura Y, Yuki D, Hayasaka T, Goto-Inoue N, Zaima N, Kunii Y, Wada A, Yang Q, Nishiura K, Akatsu H, Hori A, Hashizume Y, Yamamoto T, Ikemoto K, Setou M, Niwa S (2011) Abnormal phospholipids distribution in the prefrontal cortex from a patient with schizophrenia revealed by matrix-assisted laser desorption/ionization imaging mass spectrometry. Anal Bioanal Chem 400:1933. https://doi.org/10.1007/s00216-011-4909-3 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.McEvoy J, Baillie RA, Zhu H, Buckley P, Keshavan MS, Nasrallah HA, Dougherty GG, Yao JK, Kaddurah-Daouk R (2013) Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One 8:e68717. https://doi.org/10.1371/journal.pone.0068717 CrossRefPubMedPubMedCentralGoogle Scholar
- 30.Suvitaival T, Mantere O, Kieseppä T, Mattila I, Pöhö P, Hyötyläinen T, Suvisaari J, Orešič M (2016) Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis. Transl Psychiatry 6:e951. https://doi.org/10.1038/tp.2016.222 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.O’Gorman A, Suvitaival T, Ahonen L, Cannon M, Zammit S, Lewis G, Roche HM, Mattila I, Hyotylainen T, Oresic M, Brennan L, Cotter DR (2017) Identification of a plasma signature of psychotic disorder in children and adolescents from the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort. Transl Psychiatry 7:e1240. https://doi.org/10.1038/tp.2017.211 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar
- 35.Haring L, Koido K, Vasar V, Leping V, Zilmer K, Zilmer M, Vasar E (2015) Antipsychotic treatment reduces psychotic symptoms and markers of low-grade inflammation in first episode psychosis patients, but increases their body mass index. Schizophr Res 169:22–29. https://doi.org/10.1016/j.schres.2015.08.027 CrossRefPubMedGoogle Scholar
- 36.Balõtšev R, Haring L, Koido K, Leping V, Kriisa K, Zilmer M, Vasar V, Piir A, Lang A, Vasar E (2017) Antipsychotic treatment is associated with inflammatory and metabolic biomarkers alterations among first-episode psychosis patients: a 7-month follow-up study. Early Interv Psychiatry. https://doi.org/10.1111/eip.12457 CrossRefPubMedGoogle Scholar
- 37.Leppik L, Kriisa K, Koido K, Koch K, Kajalaid K, Haring L, Vasar E, Zilmer M (2018) Profiling of amino acids and their derivatives biogenic amines before and after antipsychotic treatment in first-episode psychosis. Front Psychiatry. https://doi.org/10.3389/fpsyt.2018.00155 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. L. Erlbaum Associates, HillsdaleGoogle Scholar
- 40.Nordstokke DW, Zumbo BD (2010) A new nonparametric levene test for equal variances. Psicol Int J Methodol Exp Psychol 31:401–430Google Scholar
- 41.TIBCO Software Inc (2017) Statistica (data analysis software system), version 13. TIBCO Software Inc., Palo AltoGoogle Scholar
- 42.Tonks KT, Coster AC, Christopher MJ, Chaudhuri R, Xu A, Gagnon-Bartsch J, Chisholm DJ, James DE, Meikle PJ, Greenfield JR, Samocha-Bonet D (2016) Skeletal muscle and plasma lipidomic signatures of insulin resistance and overweight/obesity in humans. Obesity 24:908–916. https://doi.org/10.1002/oby.21448 CrossRefPubMedGoogle Scholar
- 46.Misiak B, Stańczykiewicz B, Łaczmański Ł, Frydecka D (2017) Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: a systematic review and meta-analysis. Schizophr Res 190:18–27. https://doi.org/10.1016/j.schres.2017.03.031 CrossRefPubMedGoogle Scholar
- 49.Hanamatsu H, Ohnishi S, Sakai S, Yuyama K, Mitsutake S, Takeda H, Hashino S, Igarashi Y (2014) Altered levels of serum sphingomyelin and ceramide containing distinct acyl chains in young obese adults. Nutr Diabetes 4:e141. https://doi.org/10.1038/nutd.2014.38 CrossRefPubMedPubMedCentralGoogle Scholar